황금성게임예시 ∂ 27.rzz625.top ∂ 신 바다이야기
작성자: 나영빛차
등록일: 25-05-23 07:43
【89.rzz625.top】
ry Samsung Bioepis as a potential competitor. Through this split, Samsung Biologics expects to resolve any conflict of interest(COI) issues.
Samsung Biol주식투자동영상
ogics
Alleviating Potential Customer Concerns… Enhancing Shareholder Value
Samsung Biologics aims to completely separate its CDMO busi상한가예상종목
ness and biosimilar business, in order to resolve potential concerns from CDMO clients about operating competing businesses as well as to relieve investors’ worries about having to invest simultaneous야마토2게임
ly in two businesses with different profit models.
Samsung Biologics and Samsung Epis Holdings plan to strengthen their respective business competitiveness and enhance corporate and sharehol증권실시간방송
der value by firmly establishing independent decision-making structures through this split.
Faced with rapidly increasing external uncertainties such as changes in the international trade environment and drug price reductions, Samsung Biologics decided on the split to proactively eliminate the fundamental risk factors arising from the coexistence of the bio-CDMO and biosimilar businesses.
Samsung Epis Holdings to spearhead biosimilar and novel drug pursuits
Existing shareholders will receive shares of both companies according to the predetermined split ratio. Samsung Epis Holdings is being established by spinning off the division responsible for subsidiary management and new investments from Samsung Biologics. Kim Kyung-ah, CEO of Samsung Bioepis, will also serve as CEO of Samsung Epis Holdings.
The split will undergo procedures including submitting a securities report on July 29, and holding a shareholders’ meeting on September 16 to approve the split. The establishment date of Samsung Epis Holdings is scheduled for October 1, at which point Samsung Bioepis will be fully incorporated as a 100% subsidiary. Subsequently, the change listing of Samsung Biologics, and the re-listing of the Samsung Epis Holdings, are scheduled for October 29.
This corporate split will proceed as an equity split, where shareholders will receive shares of the new and existing companies in proportion to their shareholding ratio. Existing Samsung Biologics shareholders will receive Samsung Biologics and Samsung Bioepis Holdings shares in a ratio of 0.6503913 to 0.3496087. The split ratio was determined based on the current net asset book value.
Trading of Samsung Biologics shares will be temporarily suspended from September 29 (the day before the new share allocation record date) until October 28 (the day before the change and re-listing date).
Faster, More Flexible Decision-Making
Samsung Biologics and Samsung Epis Holdings anticipate to be able to make faster and more specialized decisions suitable for the characteristics of each business division.
Samsung Biologics, to become a purely CDMO company, plans to continue its growth based on its three key strategy -- production capacity, portfolio diversification, and global base expansion. Specifically, it will strengthen its CDMO capabilities and expand investments in new business areas such as antibodies, antibody-drug conjugates (ADC), adeno-associated viruses (AAV), and pre-filled syringes (PFS).
Samsung Epis Holdings, on the other hand, will nurture Samsung Bioepis as a leading biosimilar company by securing product portfolio of more than 20 biosimilar products. It also plans to continuously discover and invest in next-generation technology for future growth.
John Rim, CEO of Samsung Biologics, said, “We decided on this split to proactively respond to rapid changes in the global environment and to secure each business’ competitive edge through selection and focus. This will be an opportunity for both companies to accelerate growth and leap into global top-tier bio companies.”
임정요 (kaylalim@edaily.co.kr)
바다이야기모바일 ∂ 31.rzz625.top ∂ 야마토릴
사이트추천 ∂ 95.rzz625.top ∂ 빠칭코게임
성인오락황금성 ∂ 62.rzz625.top ∂ 빠찡코
바다이야기 백경 ∂ 38.rzz625.top ∂ 릴게임 황금성릴게임
바로가기 go !! 바로가기 go !!
오션파라다이스시즌7 체리마스터 공략 우주전함 야마토 먹튀 100원바다이야기 럭키세븐 황금성포커게임 다빈치게임 황금성제주도 알라딘 릴게임 럭키세븐 릴게임5만 슬롯사이트 순위 성인오락게임 슬롯무료체험 릴게임주소 바다이야기시즌7 우주 전함 야마토 2205 블랙잭추천 야마토게임방법 오션파다라이스 다운로드 야마토3게임다운로드후기 황금성연타 알라딘 릴게임 손오공예시 릴게임보물섬 온라인예시게임 백경 오리 지날 바다 최신 릴게임 검증완료릴게임 PC 슬롯 머신 게임 실시간바둑이 황금성게임후기 무료충전게임 프라그마틱 무료스핀 슬롯머신 종류 릴게임 체리마스터 바다이야기규칙 져스트릴게임 오리지널 바다이야기 야마토게임공략법 황금성용가리 릴게임 다빈치 오션파라다이스3 온라인릴게임사이트 다모아릴게임 슬롯머신 알고리즘 모바일파칭코 릴게임 다빈치 Pg 소프트 무료 체험 한게임포커 슬롯 프라 그마 틱 무료체험 바다이야기apk 바다이야기 꽁 머니 환전 릴게임5만릴게임사이다 체리마스터 다운로드 뽀빠이놀이터릴게임 오션파라다이스 먹튀 황금성 게임 장주소 릴게임오션파라다이스 파칭코사이트 황금성나비 소액 슬롯 추천 릴게임 무료머니 다빈치게임다운로드 슬롯무료체험 안전 슬롯사이트 황금성 게임 다운로드 온라인야마토주소 야마토게임하기 무료슬롯머신 신천지게임하는방법 오락실게임 손오공릴게임예시 릴게임사이다 프라그마틱환수율 오공슬롯 야마토게임공략방법 바다이야기예시종료 황금성게임다운 신천지예시 야마토게임공략 법 바다이야기디시 카지노 슬롯머신 88오락실릴게임 야마토5다운로드게임사이트 오션파라다이스7 체리마스터 어플 뽀빠이릴게임 바다이야기 게임방법 인터넷백경 슬롯 검증사이트 다빈치릴게임 양귀비게임설명 무료 야마토 게임 무료카지노게임 우주전함야마토먹튀 바다이야기프로그램 카카오야마토먹튀 바다이야기 기계 가격 최신인터넷게임 다빈치릴게임먹튀 야마토5 jQuery 슬롯 머신 일본빠칭코게임 바다이야기동영상 알라딘예시 뽀빠이놀이터릴게임 바다이야기넥슨 강원랜드슬롯머신 오션파라다이스게임사이트 사이다쿨게임 황금성3하는곳 슬롯 프라 그마 틱 무료체험 성인오락황금성 용의눈게임 프라그마틱 무료게임 야마토오락 실게임 바다이야기게임기 안전검증릴게임 파칭코슬롯 카지노 슬롯머신 잭팟 무료슬롯머신777 온라인 슬롯 배팅법 슬롯머신 무료게임 [Lim Jeong-yeo, Edaily Reporter] Samsung Biologics announced on Thursday that it will establish ‘Samsung Epis Holdings’(tentative) through an equity spin-off, completely separating its contract development and manufacturing organization(CDMO) business from its biosimilar business. The company had been increasingly facing setbacks with customers identifying Samsung Biologics’s wholly-owned subsidia우보당주식클럽ry Samsung Bioepis as a potential competitor. Through this split, Samsung Biologics expects to resolve any conflict of interest(COI) issues.
Samsung Biol주식투자동영상
ogics
Alleviating Potential Customer Concerns… Enhancing Shareholder Value
Samsung Biologics aims to completely separate its CDMO busi상한가예상종목
ness and biosimilar business, in order to resolve potential concerns from CDMO clients about operating competing businesses as well as to relieve investors’ worries about having to invest simultaneous야마토2게임
ly in two businesses with different profit models.
Samsung Biologics and Samsung Epis Holdings plan to strengthen their respective business competitiveness and enhance corporate and sharehol증권실시간방송
der value by firmly establishing independent decision-making structures through this split.
Faced with rapidly increasing external uncertainties such as changes in the international trade environment and drug price reductions, Samsung Biologics decided on the split to proactively eliminate the fundamental risk factors arising from the coexistence of the bio-CDMO and biosimilar businesses.
Samsung Epis Holdings to spearhead biosimilar and novel drug pursuits
Existing shareholders will receive shares of both companies according to the predetermined split ratio. Samsung Epis Holdings is being established by spinning off the division responsible for subsidiary management and new investments from Samsung Biologics. Kim Kyung-ah, CEO of Samsung Bioepis, will also serve as CEO of Samsung Epis Holdings.
The split will undergo procedures including submitting a securities report on July 29, and holding a shareholders’ meeting on September 16 to approve the split. The establishment date of Samsung Epis Holdings is scheduled for October 1, at which point Samsung Bioepis will be fully incorporated as a 100% subsidiary. Subsequently, the change listing of Samsung Biologics, and the re-listing of the Samsung Epis Holdings, are scheduled for October 29.
This corporate split will proceed as an equity split, where shareholders will receive shares of the new and existing companies in proportion to their shareholding ratio. Existing Samsung Biologics shareholders will receive Samsung Biologics and Samsung Bioepis Holdings shares in a ratio of 0.6503913 to 0.3496087. The split ratio was determined based on the current net asset book value.
Trading of Samsung Biologics shares will be temporarily suspended from September 29 (the day before the new share allocation record date) until October 28 (the day before the change and re-listing date).
Faster, More Flexible Decision-Making
Samsung Biologics and Samsung Epis Holdings anticipate to be able to make faster and more specialized decisions suitable for the characteristics of each business division.
Samsung Biologics, to become a purely CDMO company, plans to continue its growth based on its three key strategy -- production capacity, portfolio diversification, and global base expansion. Specifically, it will strengthen its CDMO capabilities and expand investments in new business areas such as antibodies, antibody-drug conjugates (ADC), adeno-associated viruses (AAV), and pre-filled syringes (PFS).
Samsung Epis Holdings, on the other hand, will nurture Samsung Bioepis as a leading biosimilar company by securing product portfolio of more than 20 biosimilar products. It also plans to continuously discover and invest in next-generation technology for future growth.
John Rim, CEO of Samsung Biologics, said, “We decided on this split to proactively respond to rapid changes in the global environment and to secure each business’ competitive edge through selection and focus. This will be an opportunity for both companies to accelerate growth and leap into global top-tier bio companies.”
임정요 (kaylalim@edaily.co.kr)
댓글목록
등록된 댓글이 없습니다.
